Humacyte, Inc.
HUMA
$2.53
$0.135.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -24.65% | -9.90% | |||
| Gross Profit | 27.15% | 9.90% | |||
| SG&A Expenses | 9.47% | 1.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.62% | -7.09% | |||
| Operating Income | 17.46% | 7.09% | |||
| Income Before Tax | 286.91% | 46.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 286.91% | 46.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 286.91% | 46.58% | |||
| EBIT | 17.46% | 7.09% | |||
| EBITDA | 18.75% | 7.53% | |||
| EPS Basic | 269.56% | 49.77% | |||
| Normalized Basic EPS | 61.51% | 18.72% | |||
| EPS Diluted | 269.56% | 49.77% | |||
| Normalized Diluted EPS | 61.59% | 18.72% | |||
| Average Basic Shares Outstanding | 3.55% | 6.34% | |||
| Average Diluted Shares Outstanding | 3.76% | 6.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||